The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
The role of CD56bright natural killer cells in extracorporeal photopheresis
Extracorporeal photopheresis (ECP) is an immunomodulatory therapeutic procedure which includes leukapheresis of peripheral blood, then separation of the buffy coat, and finally the irradiation of cells before re-infusion. ECP is commonly used either in combination with infliximab or monotherapy as a second-line therapy for patients with graft-versus-host disease (GvHD) who are dependent or refractory to steroids.
Pastora Iniesta from the Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Murcia, Spain, and colleagues assumed that CD56bright NK cells may increase in patients with GvHD who respond to ECP therapy and may correlate with response rates. The researchers prospectively studied blood subsets during ECP treatment.
Patients and methods:
- Enhanced flow cytometry was used to study the following molecules: CD19+, CD3+, CD3+/CD4+, CD3+/CD8+, CD3-/CD56+, CD3-/ CD56bright, and CD3-/CD56dim
- N = 32 patients were enrolled and received ECP
- aGvHD: n = 11; median age = 46 years (range, 41–62)
- cGvHD: n = 21; median age = 49 years (range, 42–57)
Key findings:
- There was a significant increase in the level of CD56 NK cells during ECP: χ2 = 33.680, P ≤ 0.001
- Higher level of CD19 cells was found: χ2 = 9.878, P = 0.043
- There was a significant difference in the level of CD56bright NK following ECP: χ2 = 35.358, P ≤ 0.001
- CD56dim NK cells significantly increased in the course of ECP: χ2 = 23.960, P ≤ 0.001
- Complete response (CR) rates: 7/11 aGvHD patients (64%) and 8/21 cGvHD cases (39%)
In conclusion, this study showed elevated levels of CD56bright NK cells after ECP therapy. The authors stated that “an early increase of CD56bright NK cells may be involved in the complex interplay of immunologic cells in exerting tolerance induced by ECP, both in aGvHD and cGvHD. This is also supported by the ability of the CD56bright to CD56dim NK cells ratio to predict for CR to the phototherapy.” These findings require independent validation including further exploring approaches for priming CD56bright NK cell expansion during ECP and revisiting the underpinning cellular mechanisms of ECP that could induce cell expansion.
References